Agilent to collaborate with quest diagnostics to extend access to the agilent resolution ctdx first liquid biopsy test

Santa clara, calif.--( business wire )--agilent technologies inc. (nyse: a) today announced an agreement with quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services. the alliance will enable providers and patients throughout the united states to access the agilent resolution ctdx first liquid biopsy next-generation sequencing (ngs) test. healthcare providers can order the test beginning today.
DGX Ratings Summary
DGX Quant Ranking